| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
43,750,000 |
| Market
Cap: |
1.49(B) |
| Last
Volume: |
2,039,919 |
Avg
Vol: |
2,275,557 |
| 52
Week Range: |
$33.97 - $33.97 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Meridian Bioscience is a life science company with principal businesses in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, Polymerase Chain Reaction master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. Co.'s reportable segments are: Diagnostics, which includes diagnostic tests and transport media; and Life Science.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
139,603 |
| Total Sell Value |
$0 |
$0 |
$0 |
$4,198,754 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
4 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Phillips David |
Director |
• • – |
2022-01-12 |
4 |
OE |
$18.54 |
$139,050 |
D/D |
7,500 |
14,045 |
|
- |
|
| Smith Julie Diana |
Sr VP, Controller, PAOOfficer |
• – – |
2022-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,036 |
|
17% |
|
| Smith Julie Diana |
Sr VP, Controller, PAOOfficer |
• – – |
2022-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
25,600 |
|
17% |
|
| Baldasare Bryan T |
Exec VP & CFO |
• • – |
2021-12-15 |
4 |
D |
$17.92 |
$35,571 |
D/D |
(1,985) |
60,929 |
|
- |
|
| Weltzien Lourdes |
EVP, Life Science |
• • – |
2021-12-15 |
4 |
D |
$17.92 |
$5,734 |
D/D |
(320) |
83,048 |
|
- |
|
| Weltzien Lourdes |
EVP, Life Science |
• • – |
2021-11-15 |
4 |
D |
$20.16 |
$86,063 |
D/D |
(4,269) |
83,368 |
|
- |
|
| Serafini-Lamanna Tony |
Executive VP-Diagnostics |
• • – |
2021-11-15 |
4 |
D |
$20.16 |
$44,997 |
D/D |
(2,232) |
40,204 |
|
- |
|
| Baldasare Bryan T |
Exec VP & CFO |
• • – |
2021-11-15 |
4 |
D |
$20.16 |
$76,749 |
D/D |
(3,807) |
62,914 |
|
- |
|
| Weltzien Lourdes |
EVP, Life Science |
• • – |
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
32,709 |
87,637 |
|
- |
|
| Weltzien Lourdes |
EVP, Life Science |
• • – |
2021-11-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(32,709) |
54,928 |
|
- |
|
| Baldasare Bryan T |
Exec VP & CFO |
• • – |
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
32,557 |
66,721 |
|
- |
|
| Baldasare Bryan T |
Exec VP & CFO |
• • – |
2021-11-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(32,557) |
34,164 |
|
- |
|
| Serafini-Lamanna Tony |
Executive VP-Diagnostics |
• • – |
2021-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,593 |
42,436 |
|
- |
|
| Baldasare Bryan T |
Exec VP & CFO |
• • – |
2021-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,593 |
66,721 |
|
- |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
56,472 |
265,131 |
|
- |
|
| Weltzien Lourdes |
EVP, Life Science |
• • – |
2021-11-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,593 |
87,637 |
|
- |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-03-17 |
4 |
AS |
$25.00 |
$750,000 |
D/D |
(30,000) |
208,659 |
|
-22% |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-03-10 |
4 |
AS |
$25.00 |
$250,000 |
D/D |
(10,000) |
238,659 |
|
-23% |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-02-16 |
4 |
AS |
$30.35 |
$71,604 |
D/D |
(2,359) |
248,659 |
|
-20% |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-02-16 |
4 |
OE |
$10.10 |
$21,028 |
D/D |
2,082 |
251,018 |
|
- |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-02-12 |
4 |
AS |
$30.14 |
$789,085 |
D/D |
(26,181) |
248,936 |
|
-30% |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-02-12 |
4 |
OE |
$10.10 |
$233,280 |
D/D |
23,097 |
275,117 |
|
- |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-02-11 |
4 |
AS |
$30.00 |
$39,601 |
D/D |
(1,320) |
252,020 |
|
-31% |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-02-11 |
4 |
OE |
$10.10 |
$11,756 |
D/D |
1,164 |
253,340 |
|
- |
|
| Kenny John P. |
Chief Executive Officer |
• • – |
2021-02-08 |
4 |
AS |
$29.86 |
$2,039,114 |
D/D |
(68,288) |
252,176 |
|
-29% |
|
894 Records found
|
|
Page 3 of 36 |
|
|
